Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta)

Abstract

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Elexacaftor-tezacaftor-ivacaftor and ivacaftor (Trikafta) 50 mg elexacaftor, 25 mg tezacaftor, and 37.5 mg ivacaftor (combination tablet) and 75 mg ivacaftor (tablet); oral 100 mg elexacaftor, 50 mg tezacaftor, and 75 mg ivacaftor (combination tablet) and 150 mg ivacaftor (tablet); oral. Indication: Treatment of cystic fibrosis in patients aged 6 years and older who have at least 1 F508del mutation in the CFTR gene.